UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 819

Sortiert nach

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

Nature communications, 2019-01, Vol.10 (1), p.259-259, Article 259

2019

Volltextzugriff (PDF)

EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression

Molecular cancer, 2019-11, Vol.18 (1), p.165-14, Article 165

2019

Volltextzugriff (PDF)

Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR- Mutant Lung Cancer

Clinical cancer research, 2017-06, Vol.23 (12), p.3139-3149

2017

Volltextzugriff (PDF)

Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models

Cancer Immunology, Immunotherapy, 2021-09, Vol.70 (9), p.2503-2515

2021

Volltextzugriff (PDF)

Macrocyclic peptide-based inhibition and imaging of hepatocyte growth factor

Nature chemical biology, 2019-06, Vol.15 (6), p.598

2019

Volltextzugriff (PDF)

Caput Medusae-like Venous Dilatation in Lung Cancer

Internal Medicine, 2019/11/15, Vol.58(22), pp.3341-3342

2019

Volltextzugriff (PDF)

Trametinib overcomes KRAS‐G12V–induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR‐mutant lung cancer

Cancer science, 2021-09, Vol.112 (9), p.3784-3795

2021

Volltextzugriff (PDF)

Effective RNA Knockdown Using CRISPR-Cas13a and Molecular Targeting of the EML4-ALK Transcript in H3122 Lung Cancer Cells

International journal of molecular sciences, 2020-11, Vol.21 (23), p.8904

2020

Volltextzugriff (PDF)

Glycogen synthase kinase‐3 inhibition overcomes epithelial‐mesenchymal transition‐associated resistance to osimertinib in EGFR‐mutant lung cancer

Cancer science, 2020-07, Vol.111 (7), p.2374-2384

2020

Volltextzugriff (PDF)

Patient‐derived xenograft models of non‐small cell lung cancer for evaluating targeted drug sensitivity and resistance

Cancer science, 2019-10, Vol.110 (10), p.3215-3224

2019

Volltextzugriff (PDF)

Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status

Cancer research (Chicago, Ill.), 2019-04, Vol.79 (7), p.1658-1670

2019

Volltextzugriff (PDF)

Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2

Oncogene, 2019-04, Vol.38 (14), p.2464-2481

2019

Volltextzugriff (PDF)

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer

Nature communications, 2020-09, Vol.11 (1), p.4607-14, Article 4607

2020

Volltextzugriff (PDF)

Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK -Rearranged/ TP53 -Mutant NSCLC via Noxa Expression

Clinical cancer research, 2021-03, Vol.27 (5), p.1410-1420

2021

Volltextzugriff (PDF)

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer

Cancer discovery, 2016-07, Vol.6 (7), p.754-769

2016

Volltextzugriff (PDF)

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1

Proceedings of the National Academy of Sciences - PNAS, 2013-12, Vol.110 (52), p.21124-21129

2013

Volltextzugriff (PDF)

Cellular stress induces non-canonical activation of the receptor tyrosine kinase EphA2 through the p38-MK2-RSK signaling pathway

The Journal of biological chemistry, 2023-05, Vol.299 (5), p.104699-104699, Article 104699

2023

Volltextzugriff (PDF)

MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR -mutant Lung Cancer

Molecular cancer therapeutics, 2017-03, Vol.16 (3), p.506-515

2017

Volltextzugriff (PDF)

Dual blockade of MET and VEGFR2 signaling pathways as a potential therapeutic maneuver for peritoneal carcinomatosis in scirrhous gastric cancer

Biochemical and biophysical research communications, 2022-04, Vol.600, p.80-86

2022

Volltextzugriff (PDF)

Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations

Molecular cancer therapeutics, 2018-01, Vol.17 (1), p.17-25

2018

Volltextzugriff (PDF)

Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review

Internal Medicine, 2022/06/01, Vol.61(11), pp.1735-1738

2022

Volltextzugriff (PDF)

Methicillin-resistant Staphylococcus aureus Necrotizing Bronchitis after Radiotherapy in Combination with Axitinib

Internal Medicine, 2022/10/01, Vol.61(19), pp.2931-2934

2022

Volltextzugriff (PDF)

A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2021-12, Vol.162, p.140-146

2021

Volltextzugriff (PDF)

Impact of MET inhibition on small‐cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway

Cancer science, 2017-07, Vol.108 (7), p.1378-1385

2017

Volltextzugriff (PDF)

Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer

Cancer letters, 2021-12, Vol.522, p.119-128

2021

Volltextzugriff (PDF)

1 – 25 von 819

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(631)
Mit Volltextzugriff
(739)

Publikationsform

Sprache

Englisch
(701)
Japanisch
(339)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression

Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR- Mutant Lung Cancer

Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models

Macrocyclic peptide-based inhibition and imaging of hepatocyte growth factor

Caput Medusae-like Venous Dilatation in Lung Cancer

Trametinib overcomes KRAS‐G12V–induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR‐mutant lung cancer

Effective RNA Knockdown Using CRISPR-Cas13a and Molecular Targeting of the EML4-ALK Transcript in H3122 Lung Cancer Cells

Glycogen synthase kinase‐3 inhibition overcomes epithelial‐mesenchymal transition‐associated resistance to osimertinib in EGFR‐mutant lung cancer

Patient‐derived xenograft models of non‐small cell lung cancer for evaluating targeted drug sensitivity and resistance

Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status

Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer

Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK -Rearranged/ TP53 -Mutant NSCLC via Noxa Expression

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1

Cellular stress induces non-canonical activation of the receptor tyrosine kinase EphA2 through the p38-MK2-RSK signaling pathway

MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR -mutant Lung Cancer

Dual blockade of MET and VEGFR2 signaling pathways as a potential therapeutic maneuver for peritoneal carcinomatosis in scirrhous gastric cancer

Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations

Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review

Methicillin-resistant Staphylococcus aureus Necrotizing Bronchitis after Radiotherapy in Combination with Axitinib

A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer

Impact of MET inhibition on small‐cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway

Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer

Suchergebnisse filtern